Factor XIII A-Subunit V34L Variant Affects Thrombus Cross-Linking in a Murine Model of Thrombosis by Duval, C. et al.
1 
 
Factor XIII A-subunit V34L variant affects thrombus cross-linking in a murine 
model of thrombosis 
 
 
 
Cédric Duval1, Majid Ali1, Waleed W. Chaudhry1, Victoria C. Ridger2, Robert A.S. 
Ariëns1, Helen Philippou1 
 
1 Thrombosis and Tissue Repair Group, Division of Cardiovascular and Diabetes 
Research; Leeds Institute of Cardiovascular And Metabolic Medicine; and 
Multidisciplinary Cardiovascular Research Centre; Faculty of Medicine and Health; 
University of Leeds; United Kingdom. 
2 Department of Cardiovascular Science; Faculty of Medicine, Dentistry, and Health; 
University of Sheffield; United Kingdom. 
 
 
 
Corresponding Author: Prof. Robert A. S. Ariëns; Thrombosis and Tissue Repair 
Group; Division of Cardiovascular and Diabetes Research; Leeds Institute of 
Cardiovascular And Metabolic Medicine; LIGHT Laboratories; Clarendon Way; 
University of Leeds; LS2 9NL; United Kingdom. Tel: +44(0)1133437734. Email: 
R.A.S.Ariens@leeds.ac.uk.  
2 
 
ABSTRACT 
 
Objectives: Factor XIII cross-links fibrin upon activation by thrombin. Activation 
involves cleavage at residue 37 by thrombin, releasing an activation peptide. A 
common polymorphism (V34L), located in the activation peptide, has been 
associated with increased activation rates and paradoxically a protective effect in 
cardiovascular disease. There is currently no data available on the effects of V34L 
from in-vivo models of thrombosis. We examined the effect of FXIII V34L on clot 
formation and cross-linking in-vivo. 
Approach and Results: We generated a panel of full-length recombinant human 
FXIII-A2 variants with amino-acid substitutions in the activation peptide to investigate 
the effect of these variants on activation rate, and we used wild-type, V34L, and 
G33A variants to study the effects of varying FXIII activation rate on thrombus 
formation in a murine model of FeCl3 injury. FXIII activation assay showed that 
residues 29, 30, 33 and 34 play a critical role in thrombin interaction. Full-length 
rhFXIII-A2 V34L has significant effects on clot formation, structure, and lysis in-vitro, 
using turbidity assay. This variant influenced fibrin cross-linking, but not size of the 
thrombus in-vivo. 
Conclusions: Mutations in the activation peptide of full-length recombinant FXIII 
regulate activation rates by thrombin, and V34L influences in-vivo thrombus 
formation by increased cross-linking of the clot. 
 
 
 
ABBREVIATIONS 
 
α2-AP α2-antiplasmin 
CAD Coronary Artery Disease 
FeCl3 Ferric Chloride 
FXIII Factor XIII 
FXIIIa Activated Factor XIII 
FXIII-A Factor XIII A-subunit 
FXIII-/- Factor XIII knockout 
G33A Alanine to Glycine variant at residue 33 
MI Myocardial Infarction 
rhFXIII Recombinant Human Factor XIII 
V34L Valine to Leucine variant at residue 34 
WT Wild Type 
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INTRODUCTION 
 
Coagulation factor XIII (FXIII) is a protransglutaminase consisting of two A-subunits, 
and two B-subunits which act as carrier for the A-subunits in plasma1. FXIII is 
activated by cleavage of an N-terminal activation peptide (residues 1-37) from the A-
subunit by thrombin, and dissociation of the transglutaminase FXIII-A dimer from the 
B-subunits in the presence of calcium2. Activated FXIII (FXIIIa) plays an important 
role in clot stabilisation by cross-linking the α- and γ-chains of fibrin3,4, and cross-
linking α2-antiplasmin (α2-AP) to fibrin5, resulting in increased resistance of the clot to 
mechanical and proteolytic challenges. 
FXIII deficiency is a rare disorder, which leads to severe bleeding6, recurrent 
miscarriage7, and impaired wound healing8. The genes encoding for both A- and B-
subunits are highly polymorphic9. The most common single nucleotide polymorphism, 
FXIII-A V34L, is located in the activation peptide and has been linked with an overall 
protective effect on thrombotic disease. Meta-analyses have shown that FXIII-A V34L 
is associated with decreased risk of myocardial infarction (MI)10 and coronary artery 
disease (CAD)11. FXIII-A V34L has also been associated with a weak protective 
effect on venous thromboembolic disease12. 
The FXIII-A 34Leu variant purified from plasma has been shown to increase 
activation rates by thrombin, and alter fibrin structure in-vitro, when compared to 
34Val13. The effects of V34L on fibrin structure depend on fibrinogen concentrations 
in the blood, with different effects at high compared with low fibrinogen14. However, 
the mechanisms by which these changes in fibrin clot structure relate to the risk of 
thrombosis are unclear, and no study has yet investigated the effects of FXIII V34L 
using in-vivo models of thrombosis.  
The aims of this study were to produce recombinant human FXIII-A2 (rhFXIII-A2) 
variants, spanning residues downstream and upstream of the thrombin cleavage site, 
and to identify residues responsible for changes in FXIII activation rates. In addition, 
we investigated the effects of rhFXIII-A2 V34L on clot structure and stability in-vitro, 
and thrombus formation using an in-vivo model. We found that FXIII residues 29, 30, 
33 and 34 in particular play a critical role in thrombin interaction. FXIII-A2 V34L has 
significant effects on clot structure in-vitro and influences fibrin cross-linking in-vivo. 
 
 
 
MATERIALS AND METHODS 
 
Materials and Methods are available in the online-only Data Supplement. 
 
 
 
RESULTS 
 
Effect of FXIII-A variants on FXIII activation and cross-linking activity in-vitro 
All rhFXIII-A2 variants generated by site-directed mutagenesis (Fig. 1A) were 
successfully expressed, except P36A, which failed to transform and express after 
repeated attempts. Of these variants, T28A, L31A, Q32A, G38A, V39A, N40A, and 
L41A showed no change in the rate of FXIII activation peptide cleavage by thrombin 
compared to WT (Fig. 1B,C). Two variants, V34L and V34M, showed increased 
activation rate, 1.43- and 1.60-fold respectively, whereas five variants showed a 
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decrease in the rate of cleavage of the FXIII activation peptide by thrombin (V29A, 
x0.62; E30A, x0.60; G33A, x0.53; V34A, x0.78; and V35A, x0.82). Variant R37A 
could not be cleaved by thrombin, confirming the specificity for arginine at the 
thrombin cleavage site. 
Variants that showed a significant change in activation rate where also analysed for 
FXIII activity rates in a kinetic pentylamine incorporation assay that is sensitive to the 
FXIII activation rate by thrombin (Fig. 1D). Those variants that had a decreased 
activation rate also exhibited a decrease in the kinetic pentylamine incorporation 
assay, reflected by a decrease in pentylamine incorporation onto casein (V29A, 
x0.86; E30A, x0.82; G33A, x0.74; V34A, x0.75), except V35A, which showed no 
change in FXIII activity. Variants V34L and V34M exhibited increased activity, 1.35- 
and 1.15-fold, in agreement with their increased activation rate. Note that previous 
studies have shown that this pentylamine incorporation assay is sensitive to the FXIII 
activation step13,15, but that once fully activated, FXIII V34L shows normal substrate 
incorporation rates16. The variants with the highest increase (V34L) and decrease 
(G33A) in FXIII activities were used for further investigation. 
 
FXIII-A2 G33A and V34L variants affect fibrin polymerisation and lysis time 
Compared to the WT (0.254±0.003), rhFXIII-A2 V34L and G33A variants showed 
decreased (0.238±0.002, p<0.01) and increased (0.265±0.003, p<0.05) maximum 
absorbency in a turbidity assay of fibrin polymerisation by thrombin (Fig. 2A) 
respectively, indicative of an effect on fibre diameter, with clots formed in the 
presence of rhFXIII-A2 V34L demonstrating thinner fibres. No difference was 
observed in terms of polymerisation rates, indicating that rhFXIII-A2 variants have no 
effect on the initial steps of fibrin formation. The lysis profile was investigated in a 
purified system, in the absence and presence of α2-AP. In the absence of α2-AP (Fig. 
2B,D), time to half-lysis was significantly increased for V34L (1.22-fold, p<0.05), but 
not G33A, indicating that fibrin clots cross-linked with V34L are harder to lyse that 
those made with WT. In the presence of α2-AP (Fig. 2C,D), time to half-lysis was 
significantly increased for WT (2.79-fold, p<0.005), compared to that of the absence 
of α2-AP. Variants V34L and G33A significantly increased (1.25, p<0.05) and 
decreased (0.83, p<0.05) time to half-lysis, respectively (Fig. 2C,D), indicating a 
potential difference in α2-AP cross-linking within the clot by these variants. 
 
FXIII-A2 V34L and G33A variants affect α2-antiplasmin cross-linking to fibrin, 
and fibrin α- and γ-chains cross-linking 
The effects of the rhFXIII-A2 variants on the lysis profile in the presence of α2-AP 
were further investigated by analysing their effects on α2-AP cross-linking to fibrin. 
Using an α2-AP incorporation assay, V34L significantly increased α2-AP cross-linking 
to fibrin compared to WT (1.63, p<0.01), whereas G33A induced a slight decrease 
which however was not significant (Fig. 2E). The  role of these variants in fibrin α- 
and γ-chains was also investigated by SDS-PAGE (Supplemental Figure). Within 2 
minutes of the initiation of clot formation, the percentage of fibrin γ-chain cross-linking 
was higher for V34L (52%), and lower for G33A (24%) compared to WT (30%), and 
virtually all γ-chains were cross-linked at 10 minutes for all variants. After 5 minutes, 
α-chain cross-linking was less than 20% for all variants, with V34L showing a higher, 
and G33A a lower, cross-linking compared to WT. After 10 minutes, the amount of 
cross-linking markedly increased, with the highest increase for V34L (66%), 
intermediate increase for WT (52%) and a lesser increase for G33A (41%). The 
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appearance of α-α cross-linking products further increased over time, with V34L 
showing a higher (85%), and G33A a lower (66%), amount of cross-linking compared 
to WT (74%) at 30 minutes. These data confirm that fibrin γ-chains are cross-linked 
more rapidly than α-chains, and that V34L increases, whilst G33A decreases, the 
cross-linking rate for both chains, compared to WT. 
 
FXIII-A2 G33A and V34L activation rates in-vivo 
The optimum amount of rhFXIII-A2 to be injected in FXIII-/- mice was determined by 
injecting various quantities of FXIII, collecting the blood after 15 minutes and 
performing a pentylamine incorporation assay on the plasma. Injection of 54µg of 
rhFXIII-A2 WT in FXIII-/- mice, was found to reproduce the phenotype of CBA/129 
mice (98±14% and 100±15% FXIII activity, respectively; data not shown). The 
remaining experiments were performed using age- and weight-matched mice for 
consistency. FXIII assay was performed on the plasma from CBA/129 mice, or FXIII-/- 
mice injected with the different FXIII-A2 variants. As per optimisation, FXIII-/- mice 
injected with rhFXIII-A2 WT had a similar FXIII activity (97±22%) compared to that of 
CBA/129 mice (100±26%). Injection of rhFXIII-A2 V34L resulted in increased 
(168±17%, p<0.05) FXIII activation rates (measured by a kinetic pentylamine 
incorporation assay sensitive to the FXIII activation step), compared to both CBA/129 
and FXIII-/- mice injected with WT, whilst G33A resulted in decreased (55±16%) FXIII 
activation rate (Fig. 3). Plasma from FXIII-/- mice injected with saline showed no FXIII 
activity (4±2%, p<0.05 compared to all other conditions). 
 
FXIII-A2 G33A and V34L variants do not affect fibrin thrombus size in-vivo 
Fibrin thrombus size was investigated by measuring the AlexaFluor488 (green) pixels 
area size. The thrombus area was unchanged over an hour for both CBA/129 
injected with saline and FXIII-/- mice injected with rhFXIII-A2 WT (Fig. 4A), indicating 
that the thrombus was already fully formed in terms of size 5 minutes (first 
measurement time-point) after FeCl3 injury, and that the injection of 54µg of rhFXIII-
A2 WT in FXIII-/- mice reproduces the phenotype of CBA/129 mice, in terms of fibrin 
clot formation. Injection of rhFXIII-A2 V34L and G33A in FXIII-/- mice did not induce 
any changes in thrombus size over time, whilst FXIII-/- mice injected with saline 
showed an increase (2.75-fold, p<0.01) in thrombus size (Fig. 4B). Immediately after 
injury (5 minutes), the thrombus size in FXIII-/- mice injected with saline was lower 
(0.58-fold, p<0.05) than that of FXIII-/- injected with rhFXIII-A2 WT and CBA/129 mice 
injected with saline (Fig. 4C). However, 65 minutes following injury, the thrombus 
size was higher (1.43-fold, p<0.05) in FXIII-/- injected with saline, compared to those 
injected with rhFXIII-A2 WT and to CBA/129 mice injected with saline (Fig. 4C). 
Figure 4D shows an example visualisation of the clots at 65 minutes, before 
background subtraction. 
 
FXIII-A2 V34L, but not G33A, increases fibrin cross-linking in-vivo 
FXIII cross-linking activity in-vivo was investigated by measuring the level of α2-AP-
based A15 peptide incorporation within the thrombus, reflected by the colocalization 
of AlexaFluor488 (green, fibrin) and AlexaFluor680 (red, A15) pixels. FXIII-/- mice 
injected with saline showed no FXIII activity throughout the duration of the 
experiment (Fig. 5B). In FXIII-/- mice injected with rhFXIII-A2 WT, the incorporation of 
A15 within the thrombus increased over the hour of data collection, in a similar 
manner to that of CBA/129 mice injected with saline (1.47- and 1.59-fold, 
respectively) (Fig. 5A), confirming that the injection of 54µg of rhFXIII-A2 WT in FXIII-/- 
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mice reproduces the phenotype of CBA/129 mice, in terms of overall cross-linking 
activity. Injection of rhFXIII-A2 G33A in FXIII-/- mice induced a lower increase (1.42-
fold) in A15 cross-linking over time compared to CBA/129 mice injected with saline 
(1.59-fold) and FXIII-/- mice injected with rhFXIII-A2 WT (1.47-fold) (Fig. 5B). 
Interestingly, FXIII-/- injected with rhFXIII-A2 V34L showed an increase (1.81-fold, 
p<0.01) in A15 incorporation over the 60 minutes period (Fig. 5B). In these mice, the 
level of A15 incorporation immediately after injury (5 minutes time point) was similar 
to that of FXIII-/- injected with rhFXIII-A2 WT  and CBA/129 mice injected with saline, 
but this was increased by 1.46- (p<0.01) and 1.42-fold respectively at 65 minutes 
(Fig. 5C). Figure 5D shows an example visualisation of the clots at 65 minutes, 
before background substraction. 
 
 
 
DISCUSSION 
 
This study provides novel insights into the effects of FXIIIa modulation on thrombus 
formation in-vivo. We found that mutations of full-length FXIII-A proteins in the region 
of the activation peptide close to the cleavage site by thrombin had significant effects 
on FXIII-A activation rates. The G33A and V34L substitutions were responsible for 
the highest decrease and increase (respectively) in activation rate by thrombin. 
These variants were shown to affect clot formation and lysis in-vitro. In-vivo, V34L 
increased cross-linking within the thrombus, but did not affect the thrombus size, 
suggesting that the effect of this single nucleotide polymorphism in human thrombotic 
disease is related to the cross-linking of proteins within the thrombus rather than an 
effect on the actual thrombus size. However, further studies using other, longer term 
models of thrombosis are required to further investigate this.  
We investigated effects of mutations downstream (N-terminal) and upstream (C-
terminal) of the cleavage site by thrombin (R37). None of the mutations upstream of 
this site were found to influence FXIII-A activation rates. Few mutations downstream 
of the thrombin cleavage site were shown to increase (V34L, V34M) or decrease 
(V29A, G33A, V34A) activation rates. The G33A variant triggered the largest 
decrease, whereas V34L showed the largest increase in activation rates. 
Interestingly, altering the nature of the amino-acid at position 34 triggered opposing 
effects on activation rate, with V34A decreasing and V34L or M increasing this rate. 
These findings highlight the importance of this particular amino-acid for the 
interaction of FXIII with thrombin. 
Previous studies using short synthetic peptides have focused on the importance of 
the FXIII amino-acid sequence downstream of the thrombin cleavage site. Peptides 
containing residues 28 to 41 exhibited an increase in kcat and a decrease in Km, 
resulting in an increased kcat/Km when 34Val was replaced by 34Leu, indicating that 
the 34Leu peptide has a higher affinity for thrombin, and is more efficiently cleaved17. 
Changes in the peptide sequence at positions V29F and V34L affected the 
interaction with thrombin, with residue 34 playing a more important role than residue 
2918. The importance of residue 34 was further highlighted by a V34A substitution 
showing a decrease in kcat/Km, indicating a decrease in hydrolysis by thrombin19. Our 
new data, using full-length rhFXIII-A2 protein, support some of these earlier findings 
based on synthetic peptides. Amino-acid substitutions at position 29 and 34 triggered 
effects on the efficiency thrombin cleavage and initial pentylamine-incorporation 
rates. Together, these data show the importance of residues 34 and 29 in the kinetics 
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of FXIII activation and show that differences in kcat/Km values at peptide level 
translate into altered function of FXIII at the protein and whole organism level. 
The effects of rhFXIII-A2 V34L on activation rate are similar to those of plasma-
purified13 and platelet-purified16 V34L. These data demonstrate that the effects on 
FXIII activation are indeed caused by the Val to Leu substitution, and indicate that 
rhFXIII-A2 behaves similarly with regards to clot formation and stabilisation as 
compared with the protein purified from plasma or platelets. The recombinant V34L 
variant decreased the maximum absorbency of the clot formed in-vitro (-6.3%) in a 
similar manner to that of V34L variant purified from human plasma (-5.2%)13 
compared with WT, indicating that both recombinant and plasma-purified FXIII-A 
V34L formed denser clots with thinner fibres20, thought to be more resistant to lysis21-
23. Additionally, a non-naturally occurring variant (G33A) showed decreased FXIII-A 
activation rate and increased maximum absorbency (+4.3%), indicating the formation 
of less dense clots with thicker fibres20. In-vitro clot lysis experiments, in the absence 
of α2-AP, showed that the recombinant V34L variant increased time to half lysis 
compared with WT, whereas G33A did not change time of half-lysis. These data 
indicate that different levels of FXIIIa cross-linking activity affect clot lysis in the 
absence of α2-AP, and are in agreement with the hypothesis that increased FXIII 
activation rates lead to denser clots that are resistant to lysis, whereas reduced FXIII 
activation rates lead to looser clots that are more amenable to lysis. This was further 
confirmed by the fact that V34L induced fibrin γ-γ and α-α cross-links at a higher rate 
than WT, whereas G33A cross-linking rates were decreased.  When α2-AP was 
added to the lysis experiments, the resistance to lysis was further increased for all 3 
variants, with V34L having the largest effect, and G33A the smallest. The rate of 
cross-linking of α2-AP onto fibrin was shown to be significantly higher for V34L 
compared to WT, whereas this was marginally decreased for G33A. The increase or 
decrease in α2-AP cross-linking further explains the differences observed for the lysis 
experiments in the presence of α2-AP. 
When both WT and V34L recombinant FXIII-A were injected into mice lacking FXIII-A 
expression, plasma collected from these mice showed similar pentylamine-
incorporation to that of human subjects possessing the different alleles. The plasma 
from mice injected with the V34L variant showed increased FXIII pentylamine-
incorporation compared to mice injected with rhFXIII-A2 WT, reproducing the 
pentylamine-incorporation levels observed in the plasma from subjects with the 
34Leu and 34Val alleles, respectively9,24. 
We next used a murine model of FeCl3 vessel injury to investigate the role of FXIII 
variants in thrombus formation. In the presence of FXIII, the clot was formed rapidly 
(within the first 5 minutes), and was stable afterwards. Similar observations were 
made with FXIII-A variants, indicating that FXIII activation rates do not affect clot area 
during thrombus formation. Interestingly, in the absence of FXIII, clot area was 
initially smaller than that in the presence of FXIII, as observed by Ali et al.25. From 10 
minutes following injury, clot area increased in the absence of FXIII to become larger 
than that observed in presence of FXIII (55 minutes onwards). We stipulate that the 
amount of fibrinogen converted to fibrin by thrombin is likely the same, but that at the 
early time-points the clot is unstable without FXIII, resulting in clots of smaller size. 
The fact that the clot area in the absence of FXIII continued to increase over 60 
minutes may be attributed to a certain level of plasticity and remodelling of the clot. 
We hypothesise that the clot area may increase due to a flattening of the clot without 
cross-linking under the pressure exhibited by the blood flow. Chernysh et al. showed 
that fibrin clots without FXIII can be remodelled in-vitro without proteolytic digestion26. 
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The authors found that in the absence FXIII, fibrin monomers and oligomers 
dissociate and re-associate from fibrin fibres. They estimated the proportion of mobile 
fibrin to be around 14% of the total fibrin incorporated into the fibres. Also, they 
showed that the addition of peptide GPRP (competing with fibrin fibre formation) to a 
preformed clot resulted in clot dissolution.  We hypothesise that similar mechanisms 
may play a role in-vivo leading to increased plasticity of the thrombus in the absence 
of FXIII. 
Cross-linking of the in-vivo thrombi was analysed using a labelled peptide substrate 
for FXIIIa (A15). We found that at initial time-points, the level of A15 incorporation 
was similar between different FXIII-A variants. However, over the course of our 
experiments, rhFXIII-A2 V34L showed a greater increase in A15 incorporation 
compared with WT. Our in-vitro studies showed that the initial rate of α2-AP 
incorporation by FXIII-A was significantly increased for V34L, in agreement with the 
increased activation rate for this variant. These data are in agreement with our in-
vitro data showing that V34L significantly increases incorporation of α2-AP onto fibrin, 
A15 corresponding to the N-terminal sequence of α2-AP. This difference in A15 
incorporation, in-vivo, cannot be attributed to a difference in FXIII activity once it has 
been fully activated, as Wartiovaara et al. showed that there is no difference in 
specific activity (activity per mg enzyme) between FXIII-A WT and V34L16. We also 
exclude differences in FXIII-A concentrations as identical amounts of protein were 
injected in age- and weight-matched mice. We hypothesise that the difference in A15 
incorporation is due to the intrinsic difference in FXIII-A activation rate and the effects 
of blood flow. Blood circulation results in a constant supply of FXIII. Due to the 
presence of thrombin at the site of thrombus formation, FXIII is activated, with the 
V34L variant being activated faster than WT. Once activated, the hydrophobic A-
subunit dissociates from the plasma carrier B-subunit, and the activated A-subunit 
binds its substrate fibrin27. Our data suggest that, with a constant supply of FXIII, and 
with a faster activation rate for FXIII V34L, more V34L than WT FXIII will be activated 
and bind to the thrombus over time, resulting in an increase in cross-linking in 
animals injected with V34L, compared to WT. It is therefore plausible that V34L could 
have a different effect on thrombus compared to WT, affecting the structure of the 
clot by increased cross-linking of the fibrin fibres, and potentially reducing fibrinolysis 
by increased incorporation of α2-AP, as shown in-vitro in this study. 
Since the original report by Kohler et al.28, several studies have investigated the 
relationship between FXIII-A V34L and cardiovascular disease. The relationship 
between FXIII-A V34L and MI has been summarised in a meta-analysis of 28 
studies10, indicating that V34L is associated with a small but significant decreased 
risk of MI. This meta-analysis highlighted some differences between ethnicity and 
gender, indicating that other factors may influence the association between FXIII-A 
V34L and MI. The relationship of the FXIII V34L with CAD had previously been 
reported in a meta-analysis of 16 studies, concluding with a small protective effect of 
this polymorphism on CAD11. Our current data from an in-vivo model of thrombosis 
due to endothelial injury suggest that any association between FXIII V34L and DVT, 
CAD or MI is more complex than merely a reduction in thrombosis . Indeed, we found 
increased cross-linking of the thrombi and a normal thrombus size in FXIII V34L mice 
compared with WT. Furthermore, cross-linking by FXIIIa in-vitro leads to the 
formation of denser clot with thinner fibres, which are slower to lyse21-23. However, 
our model has limitations in that we did not assess thrombus size by physical 
measures of the extracted thrombus. Furthermore, FeCl3 injury of the endothelium is 
relatively severe and may not represent (venous or arterial) thrombosis accurately. 
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The pathogenesis of both CAD and MI involves inflammation of the coronary artery, 
macrophage infiltration, lipid deposition and the generation of an atherosclerotic 
plaque. Thrombosis and subsequent MI is triggered by plaque rupture which 
activates platelets and coagulation29. We hypothesise that any protective effect of 
FXIII-A V34L on atherothrombotic disease may be related to plaque stability rather 
than effects on thrombosis. The development of the plaque include deposition of 
fibrin(ogen)30 and extracellular matrix proteins such as collagens31,32, fibronectin31,32, 
and vitronectin33, which are all known substrates of FXIIIa34-37. Increased cross-
linking of these elements of the plaque in subjects possessing the FXIII-A V34L allele 
could have protective effects on atherothrombosis by stabilising the plaque and 
preventing its rupture. Further studies will be required to study the role of FXIII V34L 
in models of plaque stability and atherothrombosis. 
FXIII V34L has previously also been associated with a weak protective effect in 
venous thromboembolic disease12,38-40, despite a couple of studies not finding an 
association41,42. The pathogenesis of venous disease is different from arterial 
thrombosis and involves immobilisation, stasis, inflammation and 
hypercoagulability43. Parts of thrombi in the leg or arm may break and cause emboli 
downstream in the circulation by travelling to other blood vessels, particularly in the 
lung (pulmonary embolism). It is possible that increased thrombus cross-linking by 
FXIII V34L as we have observed in our in-vivo model may stabilise the thrombus and 
prevent embolization. In addition, increased cross-linking of inhibitors of fibrinolysis 
such as α2-AP by FXIII V34L may further stabilise the thrombus. However, further 
studies will be required to investigate this hypothesis in more detail.  
In conclusion, we have shown that FXIII-A V34L influences in-vivo thrombus 
formation by increased cross-linking of the clot, without apparently affecting clot size 
in the first hour of thrombus development. The effects of this polymorphism on 
cardiovascular diseases may therefore be related to clot structure and cross-linking, 
and may include longer-term vascular effects that play a role in cardiovascular 
disease. Further studies using different of thrombosis and cardiovascular disease are 
warranted. 
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SIGNIFICANCE 
 
Thrombosis is a complication of cardiovascular diseases and is responsible for a 
large number of deaths world-wide. Factor XIII is a transglutaminase that cross-links 
the fibrin clot. A naturally occurring FXIII variant, V34L, influences thrombosis. 
Previous functional studies of V34L have been based on plasma-purified proteins or 
short synthetic peptides of FXIII-A. We have now for the first time characterised 
recombinant full-length human FXIII V34L, and demonstrated that this is a functional 
mutation. We provide insight into the role of the amino acid residues of the activation 
peptide and its interaction with thrombin. Moreover, we show that V34L changes the 
thrombotic response in a novel in-vivo model of thrombosis, by increasing the rate of 
cross-linking within the clot rather than the actual clot size. These novel findings 
demonstrate that FXIII plays a critical role in thrombosis, and that V34L is a 
functional variant which changes the response to thrombotic disease. 
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Figure 1: Effects of rhFXIII-A2 variants on activation peptide cleavage by thrombin. 
Activation of GST-rhFXIII-A2 fusion protein variants (T28 to L41; A) by thrombin (B,C) and 
kinetic analysis of incorporation of pentylamine onto casein by GST-free rhFXIII-A2 (D) were 
measured relative to the WT protein. V34L and V34M showed increased activation by 
thrombin and increased biotin incorporation rates, compared to WT (---). V39A, E30A, G33A, 
V34A, and V35A showed a decrease in both activation and biotin incorporation rates. T28A, 
L31A, Q32A, G38A, V39A, N40A, and L41A activation by thrombin was not affected, 
whereas R37A showed no activation at all, due to its location at the activation peptide 
cleavage site. P36A construct was successfully generated, but the transformation step 
repeatedly failed. * p<0.05, ** p<0.01, *** p<0.005 compared to WT. n=3. 
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Figure 2: rhFXIII-A2 V34L and G33A affect clot formation, lysis, and α2-antiplasmin 
incorporation. Turbidity (A) and turbidity/lysis in the absence (B) or presence of α2-AP (C) 
were performed using 0.5mg/ml fibrinogen, 0.1U/ml thrombin, 5mM CaCl2 and 3.7µg/ml 
rhFXIII-A2 variants. 100pM tPA, 0.24µM plasminogen and 7.5µg/ml α2-AP (when applicable) 
were added for the lysis experiments. Compared to WT, rhFXIII-A2 V34L and G33A variants 
showed significantly decreased and increased maximum absorbency (A) respectively, 
reflecting an effect on fibre thickness. Time to half lysis was significantly increased for V34L 
both in the absence (B,D) or presence (C,D) of α2-AP. G33A only showed a significant 
decrease in time to half-lysis in the presence of α2-AP (C,D). Rate of incorporation of α2-AP 
onto fibrin (E) was increased for V34L, compared to WT, but unchanged for G33A. * p<0.05, 
** p<0.01, p<0.005. n=3. 
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Figure 3: FXIII-/- mice injected with rhFXIII-A2 V34L and G33A show increased and 
decreased (respectively) FXIII activation in murine plasma. A kinetic biotinylated 
pentylamine incorporation assay sensitive to FXIII activation rates was performed on plasma 
from CBA/129 mice, FXIII-/- mice injected with 54µg of rhFXIII-A2 variants or saline. Injection 
of rhFXIII-A2 WT in FXIII-/- mice restored the FXIII activation level observed in CBA/129 mice. 
Injection of V34L significantly increased, whereas G33A decreased, FXIII activation 
compared to CBA/129 mice and FXIII-/- mice injected with rhFXIII-A2 WT. FXIII-/- mice injected 
with saline showed no FXIII activation. Kruskal-Wallis between all data (panel C) p=0.001, 
post-hoc Mann-Whitney between pairs * p<0.05. ## p<0.05. n=5. 
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Figure 4: rhFXIII-A2 variants do not affect clot size. Clot size growth was measured in 
CBA/129 mice, and mice injected with 54µg of rhFXIII-A2 variants or saline. Clot size was 
determined as a combination of area and intensity of green (fibrinogen) pixels. A) The 
phenotype of FXIII-/- mice injected with rhFXIII-A2 WT was identical to that of CBA/129 mice 
injected with saline. B) Over 60 minutes following injury, clot size was unchanged for FXIII-/- 
mice injected with rhFXIII-A2 WT, V34L, and G33A, whereas FXIII-/- mice injected with saline 
showed a significant increase of clot size. C) Comparison of the initial and final time points 
shows that 5 minutes after induction of injury, CBA/129 and FXIII-/- mice injected with rhFXIII-
A2 WT, V34L, and G33A had similar clot size, whereas FXIII-/- mice injected with saline had a 
significantly smaller clot size. 65 minutes after induction of injury, clot formed in FXIII-/- mice 
injected with saline showed a significant increase in clot size compared to the 65 minutes 
time points for CBA/129 and FXIII-/- mice injected with rhFXIII-A2 WT, and to the 5 minute 
time point of FXIII-/- mice injected with saline. D) Example visualisation of the clots at 65 
minutes, before background subtraction. Kruskal-Wallis between all data p=0.189 (5’) and 
p=0.104 (65’), post-hoc Mann-Whitney between pairs * p<0.05, ** p<0.01. n=5. 
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Figure 5: FXIII-/- mice injected with rhFXIII-A2 V34L variants show a significant increase 
in A15 incorporation within the clot. A15 incorporation within the clot was measured in 
CBA/129 mice, and mice injected with 54µg of rhFXIII-A2 variants or saline. A15 
incorporation was determined by colocalisation of red (A15) and green (fibrinogen) pixels. A) 
The phenotype of FXIII-/- mice injected with rhFXIII-A2 WT was identical to that of CBA/129 
mice injected with saline. B) Over 60 minutes following injury, A15 incorporation was 
significantly increased in FXIII-/- mice injected with rhFXIII-A2 V34L compared to those 
injected with WT, whereas mice injected with G33A showed a non-significant decrease in 
A15 incorporation. FXIII-/- mice injected with saline showed no A15 incorporation. C) 
Comparison of the initial and final time points shows that 5 minutes after induction of injury, 
CBA/129 and FXIII-/- mice injected with rhFXIII-A2 WT, V34L, and G33A had similar levels of 
A15 incorporation within the clot, whereas FXIII-/- mice injected with saline had no A15 
incorporation. 65 minutes after induction of injury, only clot formed in FXIII-/- mice injected 
with rhFXIII-A2 V34L showed a significant increase in A15 incorporation compared to both 5 
minute time point for V34L and 65 minutes time point for WT. D) Example visualisation of the 
clots at 65 minutes, before background subtraction. Kruskal-Wallis between all data (panel 
C) p=0.032 (5’) and p=0.002 (65’), post-hoc Mann-Whitney between pairs * p<0.05, ** 
p<0.01. n=5.  
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